District Court Lifts Automatic Stay and Resolves All Legacy Debt-Related Legal Proceedings as Settlement Settles Approximately $61 Million in Pre-Petition Debt (100% Thereof); $7 Million in New Capital Committed; Company Emerges with a Fortified Balance Sheet and Sharpened Focus on Growth

TEL AVIV, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in light and vision control technology, today announced a critical resolution to its balance sheet: the Tel Aviv-Jaffa District Court (the “Court”) has granted final approval, effective September 8, 2026, of the Company’s comprehensive debt settlement (the “Settlement”) under Israel’s Insolvency and Economic Rehabilitation Law, 5758-2018, in Insolvency Proceeding No. 51175-03-26. The decision draws a definitive line under a legacy capital structure and clears the way for Gauzy to operate as a debt-settled, well-capitalized public company squarely focused on its core Smart Glass business.

Settlement Highlights

  • Overwhelming Creditor Mandate: Creditors representing 98.96% of voting claims across every class voted in favor of the Settlement — including 100% of the Company’s secured lenders, OIC Investment Agent LLC and Bank Mizrahi-Tefahot Ltd. — reflecting near-unanimous support for management’s restructuring plan.
  • Approximately $61 Million of Legacy Debt Fully and Finally Resolved: The Settlement, court-confirmed on September 8, 2026, resolves substantially all of the Company’s pre-petition liabilities — secured, employee, institutional-priority and general unsecured claims alike — under a single, court-sanctioned structure.
  • $7 Million of New Equity Capital Committed: The Company has received a binding commitment for a $7 million equity investment (PIPE) led by management as a part of the court approved Settlement.  The PIPE is intended to fund immediate working capital, professional fees and priority employee obligations, and putting the Settlement on a fully-financed footing.
  • Insolvency Stay Lifted; Legacy Legal Matters Resolved; Balance Sheet De-Risked: With final Court approval now obtained, the automatic stay under Israeli insolvency law has been lifted, all legacy debt claims, executions and legal proceedings against the Company have been resolved, settled or withdrawn, and the Company’s previously scattered secured claims are being consolidated into a single, unified security structure administered by the Settlement trustees, which will be released in full as the Company completes its repayment obligations.

An Overwhelming Mandate from Every Class of Creditor

As previously, announced, the Settlement was put to a vote of the Company’s creditors at a meeting convened under the supervision of the Official Receiver and Insolvency Commissioner, following extensive negotiation among the Company, its secured lenders, its employees, and its general creditor base. The result was decisive: 98.96% of voting claims, across all classes, were cast in favor — anchored by unanimous, 100% approval from the Company’s secured lending group. Management views this outcome as a powerful vote of confidence in Gauzy’s underlying business, its technology leadership, and the credibility of the go-forward plan negotiated with the Settlement trustees, Adv. Ehud Gindes and Adv. (CPA) Simion Keidar.

Creditor Class Approval Vote
Secured lenders (OIC Investment Agent LLC and Bank Mizrahi-Tefahot Ltd.) Approved
Employees Approved
Priority institutional creditors Approved
General unsecured creditors Approved
All classes, combined 98.96%
   

Resolution of Approximately $61 Million in Legacy Liabilities

The Settlement addresses the full spectrum of the Company’s pre-petition capital structure. In the aggregate, approximately $61 million of legacy liabilities — accumulated obligations to secured lenders, employees, Israeli governmental institutions, and general trade and other unsecured creditors in Israel, the United States and Germany — are resolved under the Settlement, replacing a fragmented, contested debt stack with a single, court-approved, fully consensual arrangement. Amounts below are approximate and rounded, consistent with the Settlement documentation, and remain subject to final adjudication of debt claims by the Settlement trustees.

Legacy Liability Component Amount % of Total
Secured claims (OIC Investment Agent LLC and Bank Mizrahi-Tefahot Ltd.) ~$48.0 million ~79%
Employee claims (priority) ~$4.0 million ~7%
Priority claims to Israeli governmental institutions ~$2.9 million ~5%
General unsecured claims (Israel, U.S. and Germany) ~$5.5 million ~9%
Total pre-petition liabilities resolved ~$61.0 million 100%
     

$7 Million of New Equity Capital and a Fortified Balance Sheet

To ensure the Settlement is fully financed from day one, Gauzy has received a binding commitment for $7 million of new equity capital through a private investment in public equity (PIPE) led by Chief Executive Officer Eyal Peso together with other investors aligned with management. Of the proceeds, up to $4 million is earmarked to promptly and fully satisfy the Company’s priority employee claims, with the balance funding working capital, professional costs of the Settlement process and general corporate purposes. The new equity capital places Gauzy’s near-term liquidity on a fully-funded basis independent of the legacy claims which will be settled in accordance with the terms of the debt settlement arrangement.

Insolvency Stay Lifted and Legacy Legal Proceedings Resolved

Final Court approval terminates the automatic stay of proceedings that had applied under Israel’s Insolvency and Economic Rehabilitation Law since the process began. As a result, all claims, executions, attachments and legal proceedings brought — or that could have been brought — against the Company in respect of its pre-petition liabilities have been fully and finally settled, resolved or withdrawn pursuant to the Settlement, and creditors bound by the Settlement are precluded from pursuing independent legal action in respect of such legacy claims outside its framework. Security interests that were previously held individually by the Company’s secured creditors are being consolidated into a single, unified security arrangement administered by the Settlement trustees to support the Company’s obligations under the new equity investment and repayment structure described below, and are to be released in full as the Company completes those obligations. The result is a Company that, for the first time in this process, is free to run its day-to-day operations, capital planning and customer commitments without the overhang of contested legacy claims or active creditor litigation.

Post-Settlement Ownership and Exit Value Participation

Upon completion of the related management buyout, Gauzy’s fully diluted share capital will be held as follows:

Post-Settlement Fully-Diluted Ownership Percentage
Management (via Management Buyout) 50%
Creditors (in respect of settled legacy claims) 20%
Existing shareholders (pre-Settlement holders) 30%
   

Beyond this initial allocation, the Settlement gives creditors a further source of recovery during the term of the Settlement: 70% of the net proceeds of any Exit Event (as defined in the Settlement, generally including a sale, merger or similar liquidity event) will be applied to the Settlement fund for the benefit of creditors, up to the amount then required to satisfy the Company’s outstanding obligations under the Settlement, with the remainder retained by the Company and/or its shareholders.

A Structured, Six-Year Path to Full Resolution

Beginning April 1, 2027, the Company will make monthly payments into the Settlement fund over a 72-month (six-year) period: $200,000 per month for the first 24 months, $250,000 per month for the following 24 months, and $300,000 per month for the final 24 months — aggregate nominal payments of approximately $18 million over the life of the Settlement — supplemented, as applicable, by Exit Event proceeds as described above. Priority employee claims of approximately $4 million are being satisfied promptly out of the new equity investment proceeds, ahead of this schedule.

Management Commentary

“A 99% creditor vote — with every single one of our secured lenders voting in favor — is about as close to unanimous as a restructuring gets, and it is a direct reflection of the trust our creditors, our employees, our shareholders and our secured lenders place in this Company and in where we are headed,” said Eyal Peso, Chief Executive Officer of Gauzy. “Legacy debt is behind us. Roughly $61 million of pre-petition claims are fully and finally resolved, every lien our secured lenders held is being folded into a single structure that unwinds as we pay it down, and every pending legacy legal proceeding is resolved. With $7 million of new equity capital committed and a capital structure our team, our creditors and our shareholders all now share in, we are turning one hundred percent of our attention back to what has always defined Gauzy: our core ADAS/CMS product range for commercial vehicles, and our state-of-the-art, industry-proven Smart Glass technologies for our world-class customers across automotive, aeronautics and architecture.”

“This outcome reflects month of disciplined, good-faith negotiation among the Company, its secured lenders, its employees and its broader creditor base,” said Adv. Ehud Gindes, joint court-appointed Settlement trustee. “A 99% vote in favor, anchored by unanimous support from the secured creditor class, gave the Court a clear and well-supported basis to grant final approval and to settle 100% of its outstanding debt.”

“Following intensive efforts by all parties involved, a comprehensive and balanced Settlement arrangement has been achieved. It provides creditors with tangible repayment sources, meaningful equity participation, and a share in the Company’s future value, while supporting the Company’s continued operations and rehabilitation. This outcome is designed to maximize creditor recoveries and preserve the Company’s employees, operations, and valuable assets,” said Adv. (CPA) Simion Keidar, joint court-appointed Settlement trustee.

Looking Ahead

With its legacy balance sheet resolved and new capital committed, Gauzy is sharpening its strategic focus on two core pillars: its ADAS/CMS (Advanced Driver-Assistance Systems and Camera Monitor Systems) product range for commercial vehicles, and its Smart Glass light and vision control technologies serving the automotive, aeronautics and architecture segments. The Company intends to concentrate its resources and go-to-market efforts on these core product lines, and on converting its existing order backlog and pipeline with global customers into revenue growth. The Company will continue to provide updates on its financial position and operating performance in its ongoing filings with the U.S. Securities and Exchange Commission (the “SEC”).

Separately, the Company’s French subsidiaries remain subject to ongoing court-supervised rehabilitation proceedings in France, including the appeals the Company filed against the decisions to open the rehabilitation proceedings and the decision to grant Vision Systems assets. Gauzy continues to work closely with the relevant stakeholders toward a successful exit from those proceedings, and believes the Settlement equips the Company with important tools to support that effort — including fresh capital and the opportunity to pledge assets held by its French subsidiaries to help fund a continuation plan for their business. The Company will provide a further update on the impact and developments regarding its French operations in due course.

About Gauzy
Gauzy Ltd. is a fully-integrated light and vision control company, focused on the research, development, manufacturing, and marketing of vision and light control technologies that support safe, sustainable, comfortable, and agile user experiences across various industries. Headquartered in Tel Aviv, Israel, the company has additional subsidiaries and entities based in Germany, France, the United States, Canada, China, Singapore, and the United Arab Emirates. Gauzy serves leading brands across aeronautics, automotive, and architecture in over 60 countries through direct fulfillment and a certified and trained distribution channel.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, without limitation, statements regarding the anticipated effects, benefits and long-term impact of the Settlement; the Company’s committed new equity investment and capital structure; the timing and amount of future payments under the Settlement; the release of security interests upon completion of the Company’s obligations; participation in any future Exit Event; the Company’s liquidity, ability to continue as a going concern, and future business, financial condition and results of operations; and the Company’s strategic priorities and growth plans. These statements are often identified by words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” “continue,” “project,” “target,” “outlook” and similar expressions, or their negatives, though not all forward-looking statements contain these words. Such statements are based on management’s current expectations and beliefs and are subject to significant risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied, including, among others: the risk that actual claims ultimately allowed in the insolvency proceeding, or their treatment, may differ from current estimates; the Company’s ability to satisfy its payment and other obligations under the Settlement and the new equity investment arrangements over their respective terms; the occurrence (or non-occurrence) and timing of any Exit Event; the Company’s ability to maintain compliance with Nasdaq continued listing requirements; the Company’s ability to execute on its business strategy and convert backlog into revenue; competitive, technological and market developments affecting the smart glass, architecture, automotive, aviation and rail industries; general economic, financial and geopolitical conditions in Israel and the other jurisdictions in which the Company operates; and other risks and uncertainties described in the Company’s Annual Report on Form 20-F and in its other filings and furnishings with the SEC, including its reports on Form 6-K. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor & Media Contact:

Amanda Yevdaev, EVP Marketing
Gauzy Ltd.
PR@gauzy.com

Corporate Announcement no. 32/2026: Half-Year Report 1 January 2026  – 30 June 2026

Copenhagen, 18 September 2026

The Board of Directors and the Management have today discussed and approved the Half-Year Report of Ress Life Investments A/S for the period 1 January 2026 – 30 June 2026:

  • Ress Life Investments A/S realised a net profit after tax of USD 6,655,829 for the period 1 January 2026 – 30 June 2026. The net profit for the period corresponds to a net return on equity of 3.2%, an earnings per share of USD 57.34 and an increase in net asset value of USD 83.69 per share.
  • The period’s return was mainly driven by life expectancy updates, changes in discount rates, performance in the Legacy Portfolio, as well as the ageing of insureds and the resulting shortening of life expectancies, partly offset by administrative and staff costs. Profit for the 6-month period was on target.
  • The Company has entered into an agreement, through which a majority of policies are being sold to a market counterparty. The Company is entitled to a share of the future payouts of the disposed policies in an earnout agreement. The earnout agreement, valued at around 129 million USD as at June 30 2026, is included in the Company’s financial assets. The Company refers to corporate announcement no. 31/2026 with regard to a dispute arisen between the Company and the purchaser.
  • Equity stands at USD 225,446,310 as of 30 June 2026, corresponding to a net asset value of USD 2,722 per share compared with a net asset value of USD 2,639 at 31 December 2025.
  • During the period, 3,099 new ordinary shares were issued.
  • Management expects that the life settlements market will continue to offer attractive, diversified returns for the medium term.
  • The target net return for the Company is 7.0% in USD for 2026 and 10% for 2027 onwards. It is reasonable to assume that the yield on the underlying assets is sufficient to reach the target over the medium term.

Questions related to this announcement can be made to the Company’s AIF-manager, Finserve Nordic AB, Gustaf Hagerud, Gustaf.hagerud@finserve.se, telephone: +46 73 612 72 42 or to the Company’s Chairman Søren Andersen, email: soan@norli.dk.

Yours sincerely

Ress Life Investments A/S
The Board of Directors

Attachments

  • If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
  • Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
  • Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is associated with poor outcomes³⁻⁷

Basel, September 18, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx® (secukinumab) in polymyalgia rheumatica (PMR).⁸ The opinion supports Cosentyx use for treatment of PMR in adults who have had an inadequate response to steroids or who experience relapse during steroid taper.⁸ If approved, Cosentyx would be the first interleukin-17A (IL-17A) inhibitor approved in Europe for people living with PMR, a disease with very limited advanced treatment options.¹˒³⁻⁷

“The introduction of Cosentyx to the PMR space represents a major advancement for patients and clinicians, providing an effective treatment option while also reducing reliance on steroids – which can present challenges with long-term use,” said Prof Christian Dejaco, Director, Dept of Rheumatology, South Tyrol Health Trust, Bruneck, Italy. “I am encouraged by this positive CHMP opinion for a treatment which could both reduce flares and lower patients’ steroid exposure.”

The positive CHMP opinion is supported by results from the pivotal REPLENISH Phase III trial in which all primary and secondary endpoints were met across both Cosentyx 300mg and 150mg treatment arms, including complete sustained remission and time until patients needed additional treatment through week 52.² No new safety signals were identified in PMR patients receiving Cosentyx. The data were published in the New England Journal of Medicine and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress on June 3, 2026.²˒⁹

“People living with PMR need treatments that provide lasting remission, prevent relapses and are well-tolerated, in order to achieve the best possible long-term outcomes,” said Patrick Horber, M.D., President, International, Novartis. “Cosentyx is the first and only anti-IL-17A shown to provide sustained remission in patients with PMR, and its approval would represent an important step in transforming care for those living with this disease. Today’s positive opinion builds on the well-established impact of Cosentyx in autoimmune disease and could help establish a new standard of care for PMR in Europe.”

Following the CHMP recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months.

About Cosentyx
Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases. It is approved for use in adults with psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and hidradenitis suppurativa (HS)¹⁰⁻¹². Cosentyx is also approved for use in pediatric patients, including those with PsO, juvenile idiopathic arthritis subtypes such as juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), and in the U.S. for pediatric patients aged 12 years and older with moderate to severe HS and juvenile AS.¹⁰⁻¹⁷

About REPLENISH trial
The REPLENISH trial (NCT05767034) is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted across 27 countries, evaluating the efficacy and safety of Cosentyx in patients with polymyalgia rheumatica (PMR). Patients were randomized into three treatment arms: Cosentyx 300mg, Cosentyx 150mg, or placebo, all in combination with a 24-week steroid taper regimen. The primary endpoint of the trial was to assess whether Cosentyx 300mg s.c. plus a 24-week steroid taper is superior to placebo plus a 24-week steroid taper in achieving sustained remission at week 52. Key secondary endpoints included the proportion of patients achieving complete sustained remission at week 52, the adjusted annual cumulative steroid dose, and the time to first use of escape or rescue treatment through week 52.¹⁸

About polymyalgia rheumatica (PMR)
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.³ Relapses are frequent, affecting up to 40% of patients in the first year.⁵ Long-term steroid use is the current standard of care and carries significant risks, including osteoporosis and diabetes.¹⁹ Beyond physical complications, PMR substantially impairs quality of life through pain, fatigue, restricted mobility, and fear of relapse.⁵˒²⁰˒²¹

About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with complex, and often overlooked autoimmune and immune-mediated diseases, so they can reclaim their lives. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

  1. European Medicines Agency. Search results for “polymyalgia rheumatica.” European Medicines Agency. https://www.ema.europa.eu/en/search?search_api_fulltext=polymyalgia%20rheumatica. Accessed September 11, 2026.
  2. Stone JH, Buttgereit F, Saraux A, et al. Secukinumab in polymyalgia rheumatica. New England Journal of Medicine. 2026. doi:10.1056/NEJMoa2602567. https://www.nejm.org/doi/full/10.1056/NEJMoa2602567.
  3. Espígol-Frigolé G, Dejaco C, Mackie SL, Salvarani C, Matteson EL, Cid MC. Polymyalgia rheumatica. The Lancet. 2023;402(10411):1459–1472. doi:10.1016/S0140-6736(23)01310-7. https://doi.org/10.1016/S0140-6736(23)01310-7.
  4. Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis & Rheumatism. 1997;40(10):1873-1878.
  5. Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clinical Rheumatology. 2022;41(1):19-31. DOI: 10.1007/s10067-021-05819-z.
  6. Regeneron Pharmaceuticals, Inc.; Sanofi. Kevzara® (sarilumab) injection, for subcutaneous use: US prescribing information. Revised June 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf. Accessed September 11, 2026.
  7. European Medicines Agency. Kevzara: EPAR product information [April 25, 2022]. https://www.ema.europa.eu/en/documents/product-information/kevzara-epar-product-information_en.pdf. Accessed September 11, 2026.
  8. European Medicines Agency (EMA). Cosentyx, INN-secukinumab: CHMP post-authorisation summary of positive opinion. European Medicines Agency; 2026. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-vr-0000326984_en.pdf. Accessed September 18, 2026.
  9. Dejaco C, et al. Secukinumab in polymyalgia rheumatica: Results of the phase 3 REPLENISH trial. Oral Presentation #OP0116. Presented at: European Congress of Rheumatology (EULAR) 2026; June 3-6, 2026; London, UK.
  10. Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: Cosentyx, INN-secukinumab [Last accessed: May 2026].
  11. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. British Journal of Dermatology. 2012;167(4):717-724. doi:10.1111/j.1365-2133.2012.11099.x.
  12. Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials [Last accessed: May 2026].
  13. Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis [Press release]. Available at:  https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis [Last accessed: May 2026].
  14. Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis [Last accessed: May 2026].
  15. Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions [Last accessed: May 2026].
  16. Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa. [Press release]. Available at:https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa [Last accessed: May 2026].
  17. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
  18. ClinicalTrials.gov. Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH). Identifier NCT05767034 [June 22, 2026]. https://clinicaltrials.gov/study/NCT05767034. Accessed September 11, 2026
  19. Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R, Bombardieri S, Di Munno O. Adverse Events During Longterm Low-dose Glucocorticoid Treatment of Polymyalgia Rheumatica: A Retrospective Study. Journal of Rheumatology. 2012;39(3):552-557. doi:10.3899/jrheum.110851.
  20. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, Choy EHS, Scott DGI, Hazleman BL, Bourke B, Gendi N, Dasgupta B. Clinical Outcomes, Quality of Life, and Diagnostic Uncertainty in the First Year of Polymyalgia Rheumatica. Arthritis & Rheumatism. 2007;57(5):803-809.
  21. Mackie SL, Arun P, Padmanabhan V, Arjona A, Kullman JA. Patient perspectives on life impact and unmet needs in giant cell arteritis and polymyalgia rheumatica: insights from social media. Rheumatol Adv Pract. 2026;10(1):rkaf140. doi:10.1093/rap/rkaf140.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

 

 
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
 

Zurich, Friday, September 18, 2026 – Lufthansa has been named “World’s Best First Class Onboard Dining” at the 2026 Skytrax World Airline Awards, underscoring the strength of its partnership with gategourmet Germany and the successful launch of its groundbreaking Future Onboard Experience (FOX) program.

As Lufthansa’s strategic catering and hospitality partner, gategourmet Germany played a central role in developing and implementing the award-winning First Class dining experience, working side-by-side with Lufthansa and renowned two-Michelin-star chef Christoph Kunz over more than two years to create a new benchmark for fine dining at 35,000 feet.

“Congratulations to Lufthansa on this prestigious recognition in its centenary year. We are proud to have partnered with Lufthansa on the Future Onboard Experience (FOX), helping bring a bold vision for premium hospitality to life. This award reflects Lufthansa’s commitment to excellence and the dedication of the Lufthansa and gategourmet Germany teams, supported by 2-Michelin Star chef Christoph Kunz, creating a new benchmark for First Class dining. We look forward to continuing our journey together to elevate the travel experience for guests around the world.” said Herman Anbeek, President Europe, gategroup.

Olaf Mauthe, Senior Director Hospitality & Catering Management, Lufthansa Airlines, said: “The success of our new First Class culinary concept is the result of a true partnership. Together with gategourmet Germany and Chef Christoph Kunz, we challenged conventional approaches to inflight dining and developed a concept that brings two-Michelin-star restaurant-quality hospitality to 35,000 feet. We are proud to see this effort recognized by travelers around the world.”

From Michelin-Starred Restaurant to 35,000 Feet

As part of Lufthansa’s Future Onboard Experience (FOX), the airline’s transformation of its onboard experience, gategourmet Germany introduced Chef Christoph Kunz as a culinary partner for Lufthansa’s new First Class concept and helped translate his Michelin-starred philosophy into an award-winning inflight dining experience.

The development process brought together Lufthansa’s culinary team, Chef Kunz, and gategourmet experts led by Christoph Brandstätter, Regional Executive Chef Central Europe and Max Herzog, Senior Executive Chef for the Lufthansa Group. Through culinary workshops, tastings, and numerous test flights, the teams refined and optimized the concept before its launch across Lufthansa’s First Class network.

A Culinary Center of Excellence in Germany

To support the new First Class concept, gategourmet Germany established a dedicated team of chefs with backgrounds in Michelin-starred and fine-dining restaurants.

Today, Lufthansa First Class departures from Frankfurt and Munich benefit from highly trained culinary teams and rigorous quality controls that ensure consistency, precision, and product excellence.

The result is a dining experience that successfully translates two-star gastronomy into a large-scale airline operation while maintaining the standards expected by Lufthansa’s most discerning guests.

Raising the Standard of Airline Dining

Introduced in March 2026, the new First Class dining concept was built around greater choice, personalization, and elevated presentation. The collaboration encompassed the full spectrum of the onboard culinary experience, including menu development, service concepts, operational processes, customer testing and onboard equipment. Complementing the culinary offering, deSter, a gategroup brand, developed the FOX serviceware and equipment concept, balancing premium design, operational efficiency, and sustainability.

The recognition highlights the strength of the partnership between Lufthansa and gategroup and reinforces gategroup’s role as a trusted innovation partner for leading airlines worldwide.

About gategroup

gategroup is the leading global provider of airline catering, retail-on-board, and hospitality products and services. Headquartered in Zurich, Switzerland, the company serves millions of passengers through a network of nearly 300 locations in more than 68 countries. By leveraging innovation and operational expertise, gategroup partners with the world’s leading airlines to create exceptional travel experiences. Learn more at www.gategroup.com

mediacontact@gategroup.com

  • Second consecutive year and tenth time the airline has taken home this honour since 2010
  • Airline also wins World’s Best Business Class Lounge Dining for the Air Canada Signature Suite in Toronto for the third consecutive year
  • Other honours include Best Cabin Crew in Canada and Best Economy On Board Catering in North America

MONTRÉAL, Sept. 18, 2026 (GLOBE NEWSWIRE) — Air Canada today was named the Best Airline in North America at the 2026 Skytrax World Airline Awards for the second year in a row. It represents the tenth time Air Canada has received this honour since 2010. Presented this year in London, UK, the Skytrax awards, which are based on customer satisfaction surveys of millions of global travellers, also recognized once again the Toronto Air Canada Signature Suite as the World’s Best Business Class Lounge Dining for the third straight year. Air Canada also took home additional honours for Best Cabin Crew in Canada, Best Economy On Board Catering in North America and Best Business Class Lounge in North America.

Air Canada Named Best Airline in North America at the 2026 Skytrax World Airline Awards

Air Canada also moved up two spots and ranks 17th among the World’s Top 100 Airlines in 2026, the only North American carrier to make top 20.

“We’re incredibly proud to be named Best Airline in North America. On behalf of 40,000 Air Canada coworkers around the world, we thank our customers for their trust, loyalty, and for choosing to fly with us. Their recognition is especially meaningful because it reflects the views of the people who experience our products and services firsthand. This award belongs to our people, whose professionalism, dedication, and genuine care for our customers make moments of exceptional hospitality possible across our global network. I’m honoured to accept this recognition on their behalf and thank them for their commitment to elevating the customer experience,” said Mark Nasr, Executive Vice President & Chief Operations Officer at Air Canada.

These awards recognize Air Canada’s leadership in the industry and its continued commitment to enhancing every stage of the travel journey, as recognized by customers worldwide. Over the past several years, the airline has introduced fast, free Wi-Fi sponsored by Bell, a mobile app that is an industry reference with its expanded functionality, complimentary premium snacks, wine and beer on all flights, and additional content on its award-winning in-flight entertainment system. Air Canada has also invested in new and upgraded lounges, streamlined airport processes, its award-winning Aeroplan loyalty program, and seamless intermodal travel options that allow customers to book air and ground transportation on a single ticket. Earlier this year, the airline also introduced the next generation of its cabin design with the entry into service of the Airbus A321XLR. The Glowing Hearted design delivers a distinctly Canadian experience, emphasizing comfort, care, and connection for all customers on every flight.

About the Air Canada Signature Suite 

Air Canada presents two Signature Suite lounges for departing international customers at Toronto Pearson and Vancouver International airports. Recognized by the Skytrax World Airline Awards for the World’s Best Business Class Lounge Dining at the Air Canada Signature Suite at Toronto Pearson, our menu showcases Canada’s diverse ingredients through refined, locally inspired dishes that evolve with the seasons. The experience is complemented by a curated wine list featuring standout Canadian and international labels, emphasizing craftsmanship and the unique character of Canada’s wine regions. Our cocktail menu, crafted with premium ingredients and creative flair, draws from global trends to deliver a memorable, elevated experience. Designed to evoke a Canadian sense of place, each Signature Suite reflects the beauty, warmth, and sophistication of the country it represents.

About the Skytrax World Airline Awards 

The World Airline Awards are wholly independent and impartial, introduced in 1999 to provide a customer satisfaction study that is truly global. Travellers across the world vote in the largest airline passenger satisfaction survey to determine the award winners. The awards are referred to by media around the world as “the Oscars of the aviation industry”. Skytrax pay all costs of the Survey and Awards process, with no sponsorship. There is no survey entry or registration fee, and awards event is free to attend and there are no charges or royalty payments for use of the award logos and results. The online survey operated from September 2025 to August 2026, and more than 100 customer nationalities participated. All survey entries were screened to identify IP and user information, with duplicate, suspect and ineligible entries deleted. Over 300 airlines are featured in the 2025/2026 survey results. The customer survey was offered in English, French, Portuguese, Spanish, Turkish, Chinese, Japanese and Korean.

About Air Canada

Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals, and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:        media@aircanada.ca

Internet:        aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dc0f0834-74c4-4ae4-86e5-74d1d9509ad3

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tate & Lyle plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
17/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
        If it is a cash offer or possible cash offer, state “N/A”
 

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

29 1/6p ordinary
(ISIN-GB00BP92CJ43)
  Interests

Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives:

                       10,861,233

2.44%    
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        

        TOTAL:

10,861,233 2.44%    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale

Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit (GBP)
29 1/6p ordinary CFD Increasing a long position                       2,133,714

5.5800

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
 

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
 

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 18/09/2026
Contact name: Alex McMillan
Telephone number: 646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Bid procedure, 2026-09-25
Bonds SWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01

SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01

Bid date 2026-09-25
Bid times 09.00-10.00 (CET/CEST) on the Bid date
Offered volume (corresponding nominal amount) 3113: 200 million SEK +/-200 million SEK

3111: 200 million SEK +/-200 million SEK

Highest permitted bid volume (corresponding nominal amount) 3113: 200 million SEK per bid

3111: 200 million SEK per bid

Lowest permitted bid volume (corresponding nominal amount) SEK 10 million per bid
Expected allocation time Not later than 10.15 (CET/CEST) on the Bid date
Delivery and payment date 2026-09-29
Settlement amount To be paid to the Riksbank’s account in Euroclear Sweden AB’s securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK

Stockholm, 2026-09-18

This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.      KEY INFORMATION

(a)   Full name of discloser Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a)

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates

Use a separate form for each offeror/offeree

DCC plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)  
(e)   Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure

17/09/2026
(f)   In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

No

2.      INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)

Class of relevant security
(Note 3)
€0.25 Ordinary Shares

(ISIN – IE0002424939)

  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled        
(2)   Cash-settled derivatives 1,670,372

1.96%

   
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell        
Total

1,670,372

1.96%    

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.      DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)      Purchases and sales

Class of relevant
security
Purchase/sale Number of
securities
Price per unit
(Note 5)

(b)      Cash-settled derivative transactions

Class of
relevant
security
Product
description
e.g. CFD
Nature of dealing Number of
reference
securities
(Note 6)
Price
per unit

€0.25 Ordinary Shares CFD Increasing a long position 130,000 GBP 63.6500

(c)      Stock-settled derivative transactions (including options)

(i)      Writing, selling, purchasing or varying

Class of
relevant
security
Product
description e.g. call
option
Writing, purchasing, selling, varying
etc.
Number
of
securities
to which
option
relates
(Note 6)
Exercise
price per
unit
Type
e.g.
American,
European
etc.
Expiry
date
Option
money
paid/
received per unit

(ii)      Exercise

Class of
relevant
security
Product
description
e.g. call
option
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
Details Price per unit (if
applicable)
(Note 5)

4.      OTHER INFORMATION

(a)      Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

(b)      Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 

(c)        Attachments

Is a Supplemental Form 8 attached? NO

Date of disclosure 18/09/2026
Contact name Alex McMillan
Telephone number 646 282 5805

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

NOTES ON FORM 8.3

1.      See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

2.      See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

3.      See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

4.      See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

5.      If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

6.      See Rule 2.5(d) of Part A of the Rules.

7.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Schindellegi, Switzerland – 18 September 2026

Trifork Group AG
Company announcement no. 55/2026

Reporting of transactions made by persons discharging managerial responsibilities

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name Jørn Larsen
2. Reason for the notification
a) Position/status CEO
b) Initial notification/
Amendment
Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Trifork Group AG
b) LEI 8945004BYZKXPESTBL36
4.1 Details of the transaction(s)
a) Description of the financial instrument, type of instrument

Identification code

Shares

ISIN CH1111227810

b) Nature of the transaction Sale
c)

Price(s) and volume(s)

Price(s) Volume(s)
107.00
106.50
106.50
345
1,029
1,003
d) Aggregated information
—
Aggregated volume —
Price
Total volume: 2,377
Average price: DKK 106.57
Total value: DKK 253,323
e) Date of the transaction 15 September 2026
16 September 2026
17 September 2026
f) Place of the transaction Nasdaq Copenhagen (XCSE)

Contact
Frederik Svanholm, Group Investment Director, frsv@trifork.com, +41 79 357 7317

About Trifork Group
Trifork (Nasdaq Copenhagen: TRIFOR) is a global technology company specializing in designing, building, and operating advanced software for enterprise and public sector customers. With 1,118 FTEs across 16 countries, Trifork serves as an end-to-end technology partner to organizations in complex and regulated industries, including public administration, healthcare, financial services, energy, and aviation.

Learn more at trifork.com

Attachment

The 2026 MICHELIN Key Hotels: A Guide to the Global Selection

Inspectors just unveiled the global MICHELIN Keys for 2026
Inspectors just unveiled the global MICHELIN Keys for 2026
  • 189 hotels across Saudi Arabia, Qatar, Bahrain, Oman, Kuwait, the United Arab Emirates, Jordan, Morocco, Egypt, South Africa and India receive the MICHELIN Key distinction
  • 9 Hotels Receive the Three MICHELIN Keys
  • 2 Properties Recognised Among the MICHELIN Guide’s Four Special Awards

DUBAI, United Arab Emirates, Sept. 18, 2026 (GLOBE NEWSWIRE) — The MICHELIN Guide has unveiled its 2026 MICHELIN Key selection, recognising 2,832 hotels worldwide for exceptional stays. Following months of anonymous inspections, the global selection welcomes nearly 470 newly distinguished hotels across 79 destinations, reflecting a hospitality landscape shaped by increasingly immersive, personalised and experiential stays.

Across the Middle East, Africa and India, 189 hotels across 11 destinations have been awarded MICHELIN Keys, bringing together an increasingly diverse hospitality landscape, from landmark city hotels and historic palaces to desert retreats, safari lodges, contemporary resorts and intimate properties shaped by their surroundings.

Of the 189 hotels selected, 130 receive One MICHELIN Key, 50 receive Two MICHELIN Keys and 9 receive the highest distinction of Three MICHELIN Keys.

More than a measure of luxury, the 2026 selection reflects the different ways a hotel can create an exceptional stay: through architecture and design, a distinctive personality, deeply considered service, a strong connection to its setting or an experience that gives travellers a reason to discover a destination.

From Desert Landscapes to Historic Palaces: A Hospitality Landscape Shaped by Place

The 2026 selection reflects a broader evolution in hospitality, with distinctive design, immersive experiences and a stronger sense of place increasingly shaping the way travellers experience a destination.

That diversity is particularly visible across the region.

In Saudi Arabia, 17 hotels receive MICHELIN Keys, including Desert Rock Resort, which receives Three MICHELIN Keys as well as the MICHELIN Guide Architecture & Design Award. Set within the Hijaz Mountains, the property is recognised for its striking integration with the surrounding landscape.

The United Arab Emirates receives 25 MICHELIN Keys, including a Three MICHELIN Keys distinction for Atlantis The Royal, Dubai, while Qatar has 11 Key hotels. The wider Gulf selection also includes three Key hotels in Bahrain, 3 in Oman and 2 in Kuwait, alongside 5 hotels in Jordan.

In Morocco, 31 hotels receive MICHELIN Keys, including Three MICHELIN Key properties Kasbah Tamadot and La Mamounia, reflecting the country’s distinctive blend of architecture, heritage, landscape and contemporary hospitality. Egypt adds 13 MICHELIN Key hotels to the regional selection, including 2 Two MICHELIN Key properties, further expanding the recognition of the region’s diverse hospitality offering.

Further south, South Africa has 32 MICHELIN Key hotels, including 3 Three MICHELIN Key properties. Londolozi Game Reserve also receives the MICHELIN Guide Local Gateway Award, recognising its distinctive connection to its setting and its approach to hospitality.

India has the largest number of MICHELIN Key hotels among the 11 destinations in this regional selection, with 47 properties recognised. Two historic properties, Taj Falaknuma Palace in Hyderabad and Taj Lake Palace in Udaipur, receive Three MICHELIN Keys, bringing the distinction to 2 of India’s most distinctive palace hotels.

Together, the selection demonstrates the breadth of hospitality being recognised by the MICHELIN Guide, where an exceptional stay can take many forms and where individuality, character and a meaningful relationship with place are central to the experience.

Nine Hotels Receive the MICHELIN Guide’s Highest Hotel Distinction

Among the 189 hotels recognised across the 11 destinations, 9 receive Three MICHELIN Keys, the MICHELIN Guide’s highest hotel distinction.

The 2026 Three MICHELIN Key selection includes:

  • Desert Rock Resort, Saudi Arabia
  • Atlantis The Royal, Dubai, United Arab Emirates
  • Kasbah Tamadot, Morocco
  • La Mamounia, Morocco
  • Royal Malewane, South Africa
  • Delaire Graff Estate, South Africa
  • Londolozi Game Reserve, South Africa
  • Taj Falaknuma Palace, India
  • Taj Lake Palace, India

Together, these properties represent distinctly different interpretations of an extraordinary stay, spanning desert landscapes, safari experiences, historic palaces, destination resorts and landmark urban hospitality.

A Global Selection Reflecting a Changing Hospitality Landscape

The regional selection forms part of the MICHELIN Guide’s second global MICHELIN Key selection, which now includes 2,832 Key hotels worldwide, comprising 2,020 One-Key, 657 Two-Key and 155 Three-Key hotels.

Across the global selection, nearly 470 hotels have been newly distinguished, with MICHELIN Keys now spanning 79 destinations. The 2026 selection also sees the distinction introduced for the first time in 10 destinations, further expanding the MICHELIN Guide’s presence across the world of hospitality.

For Gwendal Poullennec, International Director of the MICHELIN Guide, the continued expansion of the hotel selection reflects a rapidly evolving hospitality sector:

“This second global selection of the MICHELIN Keys reflects the extraordinary momentum driving the hospitality sector once again this year. With 470 newly distinguished establishments, we are witnessing a continuous upscaling of the offering, driven by even more creative and ambitious projects. All around the world, hoteliers are reinventing the stay experience through more immersive, personalized, and experiential concepts.

This capacity for innovation is expressed both in must-visit destinations and in emerging tourist markets. Often driven by visionary independent hotelkeepers, this evolution in concepts is now inspiring the industry as a whole. It is also supported by investments from major international groups, which are helping to accelerate this transformation. The 2026 selection thus celebrates the diversity, vitality, and excellence of an ever-evolving sector, one that continues to push the boundaries of the hospitality experience and invite travelers to discover new destinations.”

Two Regional Properties Among the MICHELIN Guide’s Four Special Awards

The 2026 MICHELIN Guide selection also includes four Special Awards recognising hotels whose distinctive approaches stood out to MICHELIN Guide inspectors.

Two of the four awards are represented within the Middle East and Africa selection.

The MICHELIN Guide Architecture & Design Award goes to Desert Rock Resort in Umluj, Saudi Arabia, recognised for its striking integration into the landscape of the Hijaz Mountains.

The MICHELIN Guide Local Gateway Award goes to Londolozi Game Reserve in Kruger, South Africa, highlighting a pioneering safari property with a longstanding connection to its landscape and the culture of the region.

The global selection also includes the MICHELIN Guide Wellness Award, presented to Schloss Elmau Luxury Spa Retreat & Cultural Hideaway in Germany, and the MICHELIN Guide Opening of the Year Award, presented to Airelles Palladio Venice in Italy.

Selected Anonymously and Independently by MICHELIN Guide Inspectors

The MICHELIN Key is the hotel distinction awarded by the MICHELIN Guide, equivalent to the MICHELIN Star for restaurants. It highlights the most outstanding hotels within the MICHELIN Guide’s hotel selection.

MICHELIN Guide inspectors visit hotels anonymously and independently, assessing each property against five universal criteria:

  • Excellence in architecture and interior design
  • Quality and consistency of service
  • Overall personality and character
  • Value for the price
  • A significant contribution to the neighbourhood or setting

One MICHELIN Key: A very special stay.

Two MICHELIN Keys: An exceptional stay.

Three MICHELIN Keys: An extraordinary stay.

The full 2026 MICHELIN Key selection is available across the MICHELIN Guide’s digital platforms, where travellers can explore the hotels, discover their MICHELIN Key distinctions and find inspiration for their next stay.

The 2026 MICHELIN Key Selection at a Glance

  • 189 MICHELIN Key hotels across 11 destinations in the Middle East, Africa and India
  • 130 One MICHELIN Key
  • 50 Two MICHELIN Keys
  • 9 Three MICHELIN Key
  • 2,832 MICHELIN Key hotels worldwide
  • 2,020 One MICHELIN Key hotels worldwide
  • 657 Two MICHELIN Key hotels worldwide
  • 155 Three MICHELIN Keys hotels worldwide

About the MICHELIN Guide Hotel Selection

The MICHELIN Guide’s hotel selection is based on the work of its inspectors, who travel anonymously and independently to identify hotels offering outstanding experiences. The selection spans a wide range of properties, from historic landmarks and grand hotels to independent boutiques, remote retreats and innovative new openings.

The MICHELIN Key is the hotel distinction awarded by the MICHELIN Guide, equivalent to the MICHELIN Star for restaurants. Introduced in 2024 across 15 destinations in North America, Europe and Asia, the MICHELIN Key has since expanded into a global distinction.

Hotels are awarded One, Two or Three MICHELIN Keys, according to the level of experience they offer:

. One MICHELIN Key: A very special stay.

. Two MICHELIN Keys: An exceptional stay.

. Three MICHELIN Keys: An extraordinary stay.

About Michelin:

Michelin is building a world-leading manufacturer of life-changing composites and experiences. Pioneering engineered materials for more than 130 years, Michelin is uniquely positioned to make decisive contributions to human progress and to a more sustainable world. Drawing on its deep know-how in polymer composites, Michelin is constantly innovating to manufacture high-quality tires and components for critical applications in demanding fields as varied as mobility, construction, aeronautics, low-carbon energies, and healthcare. The care placed in its products and deep customer knowledge inspire Michelin to offer the finest experiences. This spans from providing data- and AI-based connected solutions for professional fleets to recommending outstanding restaurants and hotels curated by the MICHELIN Guide. Headquartered in Clermont-Ferrand, France, Michelin is present in 175 countries and employs 122,600 people. (www.michelin.com).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4685ff25-ec56-41e3-bf8c-b37729ef6178

 

CONTACT: Press Contact  

BPG Group
michelinguide@bpggroup.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.